The private equity owners of Stada are close to mandating investment banks to sell the German generic drugmaker or list it on the stock exchange, newspaper Handelsblatt reported on Wednesday, citing financial sources.
The company, majority-owned (since 2017) by buyout firms Bain and Cinven, who you can meet at the UK Private Equity Conference, sells consumer healthcare products such as painkillers and sunscreen lotions, as well as biosimilar and generic drugs, which are cheaper copies of established pharmaceuticals that have lost patent protection.
Get the week’s top news delivered directly to your inbox – Sign up for our newsletter
Stada declined to comment. A spokesperson for Cinven could not immediately be reached for comment.
The Handelsblatt report said the most likely option for now was the sale of a minority stake in Stada to a third investor, and said Stada could be valued at up to 15bn euros ($16.10 bn) in a transaction.
Source: Yahoo! Finance
Can’t stop reading? Read more
Blackstone explores launch of dedicated private credit secondaries strategy
Blackstone explores launch of dedicated private credit secondaries strategy Blackstone is...
Blue Owl and Koda Capital unlock US private credit access for Australian investors
Blue Owl and Koda Capital unlock US private credit access for Australian investors Blue Owl...
Orangewood backs major 7 Brew franchisee as brand continues rapid US expansion
Orangewood backs major 7 Brew franchisee as brand continues rapid US expansion Orangewood Partners...